Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.
Case: A 73-Year-Old Man with EGFR+ NSCLC
Clinical Presentation:
Past Medical History:
Social History:
Initial Clinical Workup and Diagnosis:
Physical Examination
Pulmonary Function Tests
Imaging Studies:
Diagnostic Procedure:
Neoadjuvant Therapy and Surgical Resection:
Surgical Pathology Report:
Six Months Later:
Second Line Systemic Therapy:
Repeat Imaging at 8 Weeks:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Joshua K. Sabari, MD.
EGFR exon 20 insertions are rare, comprising about 5% to 10% of EGFR mutations and 1% of non–small cell lung cancer. Standard EGFR tyrosine kinase inhibitors like osimertinib are ineffective for exon 20–mutated lung cancer due to steric hindrance preventing drug binding.
Mobocertinib initially showed promise but failed to improve outcomes over chemotherapy in a phase 3 trial, leading to its removal from clinical use. More recently, the antibody-drug conjugate amivantamab demonstrated response rates around 40% in exon 20-inserted NSCLC.
The phase 3 PAPILLON trial of amivantamab plus chemotherapy vs chemotherapy alone as first-line treatment was recently presented and published, nearly doubling progression-free survival from 6 to 7 months with chemotherapy alone to 11.5 to 12 months with amivantamab plus chemotherapy, with a hazard ratio under 0.4. This establishes a new standard of care for this patient population.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More